In an industry dominated by massive consultancies and slow-moving tech giants, 81qd is executing a precision strike: 30 people, $3.5M in revenue, and a laser focus on the intersection of rare disease diagnosis and commercial pharma strategy. They aren't building general AI tools; they're building medical-grade analytics that actually move the needle on patient outcomes.

"They aren't chasing scale; they're chasing signal. In pharma analytics, 30 focused experts beat 300 generalists every time."

The tech stack tells a story of pragmatic efficiency. They leverage jQuery, Tailwind CSS, and Bootstrap—proven, stable technologies that prioritize speed and reliability over bleeding-edge frameworks. This isn't a startup burning cash on experimental tech; it's a lean operation building robust platforms for regulated environments. The presence of Google Analytics and lazy loading shows they understand performance and data, even if their public footprint is minimal.

• Rare Disease Diagnosis Acceleration: Using ML to speed up identification where data is scarce.
• Commercial Analytics for Pharma: Driving product adoption and therapy adherence through targeted data strategy.
• Cross-Functional Expertise: Merging data science, medical strategy, and marketing under one roof.